Published in:
Open Access 01-12-2017 | Original Research Article
Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
Published in: Clinical Pharmacokinetics | Issue 12/2017
Login to get accessAbstract
Introduction
Obesity is associated with many pathophysiological changes that may result in altered drug metabolism. The aim of this study is to investigate the influence of obesity on the pharmacokinetics of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) through a combined analysis in morbidly obese patients and non-obese healthy volunteers.
Methods
In this analysis, data from 20 morbidly obese patients [mean body mass index 49.9 kg/m2 (range 37.6–78.6 kg/m2) and weight 151.3 kg (range 112–251.9 kg)] and 20 healthy volunteers [mean weight 70.6 kg (range 58–85 kg)] were included. Morbidly obese patients received 10 mg of intravenous (I.V.) morphine after gastric bypass surgery, with additional morphine I.V. doses as needed. Healthy volunteers received an I.V. bolus of morphine of 0.1 mg/kg followed by an infusion of 0.030 mg kg−1 h−1 for 1 h. Population pharmacokinetic modeling was performed using NONMEM 7.2.
Results
In morbidly obese patients, elimination clearance of M3G and M6G was decreased substantially compared with healthy volunteers (p < 0.001). Regarding glucuronidation, only a slight decrease in the formation of M6G and a delay in the formation of M3G was found (both p < 0.001). Obesity was also identified as a covariate for the peripheral volume of distribution of morphine (p < 0.001).
Conclusion
Metabolism of morphine is not altered in morbidly obese patients. However, decreased elimination of both M3G and M6G is evident, resulting in a substantial increase in exposure to these two metabolites. A rational explanation of this finding is that it results from alterations in membrane transporter function and/or expression in the liver.
ClinicalTrials.gov identifier: NCT01097148.